Latest news with #HackensackMeridianNeuroscienceInstitute
Business Wire
6 days ago
- Health
- Business Wire
ZAP Surgical Celebrates 5,000th Patient Treated Globally with ZAP-X
SAN CARLOS, Calif.--(BUSINESS WIRE)--ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced the treatment of the 5,000th patient using its ZAP-X ® Gyroscopic Radiosurgery ® platform — a major milestone reflecting the platform's rapid worldwide adoption. The case was performed at Hackensack Meridian Neuroscience Institute at Jersey Shore University Medical Center in Neptune, New Jersey. The patient, Christopher Czerwinski, a 64-year-old Trauma & ICU Nurse, was treated for a right-sided cavernous sinus meningioma. Mr. Czerwinski first noticed diplopia (double vision) nearly two years ago, with symptoms peaking in April 2025 while on vacation at Disney World with his wife — where he humorously recalls seeing two Cinderella castles. An ophthalmologist subsequently referred him for further testing, which led to an MRI and diagnosis. His condition was originally managed with prism glasses and contact lenses. Mr. Czerwinski ultimately selected Jersey Shore University Medical Center for his radiosurgical care due to the capabilities of the ZAP-X platform and the proven expertise of the medical team. Mr. Czerwinski underwent ZAP-X treatment and tolerated the procedure exceptionally well, resuming his active lifestyle immediately thereafter. 'Stereotactic radiosurgery continues to redefine how we manage challenging cranial conditions,' said Shabbar F. Danish, M.D., FAANS, chair of Neurosurgery, Hackensack Meridian Neuroscience Institute at Jersey Shore University Medical Center and professor of Neurosurgery, Hackensack Meridian School of Medicine. 'With the precision and versatility of ZAP-X, we were able to deliver focused treatment while minimizing exposure to surrounding critical structures. Mr. Czerwinski's case is a prime example of how we can address complex tumors while preserving quality of life.' An avid runner and budding pianist, Mr. Czerwinski also enjoys photography, working out with his wife, and spending time with friends and family. As a healthcare provider himself, he expressed deep appreciation for the compassionate care he received and the non-invasive nature of the ZAP-X procedure. 'I'm pleased our clinical experts have enabled the communities we serve to receive this advanced procedure at our academic medical center, without the need to travel far from home,' said Vito Buccellato, MPA, LNHA, president and chief hospital executive of Jersey Shore University Medical Center. The ZAP-X platform represents a new frontier in cranial radiosurgery. By employing gyroscopic beam delivery, ZAP-X can direct radiation from thousands of angles to concentrate dose on the tumor while sparing healthy brain tissue and helping protect nearby organs at risk, such as the optic nerves and brainstem. The procedure is painless, incisionless, and often completed in a single outpatient session — without the need for anesthesia or hospital admission. 'The treatment of our 5,000th patient not only represents a numerical milestone, but a reaffirmation of our mission to make brain radiosurgery safer, smarter, and more accessible,' said John R. Adler, M.D., founder and CEO of ZAP Surgical, and Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University. ZAP-X is the first and only dedicated cranial SRS platform that does not require radioactive Cobalt-60. Instead, it uses a modern linear accelerator to generate radiation, eliminating the safety, storage, and regulatory challenges associated with isotope-based systems. Furthermore, ZAP-X is the only vault-free solution in its category, thereby allowing installation in clinical settings with interior and exterior facing windows. 'We recruited experts in their fields, Dr. Shabbar Danish and Dr. Timothy Chen, in part so that we could add to the available, leading-edge treatment technologies at Jersey Shore and HMH,' said Kenneth N. Sable, M.D., MBA, FACEP, president, Acute Hospital Division, Hackensack Meridian Health. 'I'm thrilled that the 5,000th patient to receive ZAP-X treatment is from our local community.' For information about Jersey Shore University Medical Center's ZAP-X program, visit About ZAP Surgical Systems, Inc. ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X ® Gyroscopic Radiosurgery ® platform. ZAP was founded in 2014 by Dr. John R. Adler, Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University. Dr. Adler is also renowned as the inventor of the CyberKnife ® system and founder of Accuray, Inc. The ZAP-X platform incorporates a unique vault-free design that typically eliminates the need for costly shielded treatment rooms. ZAP-X also utilizes a modern linear accelerator to eliminate legacy use of Cobalt-60. Learn more at and follow us on LinkedIn. Hackensack Meridian Health is a leading not-for-profit health care organization and New Jersey's largest, most comprehensive, and integrated health network. Our network includes 18 hospitals, more than 500 patient care locations, and a complete range of services from innovative research and life-enhancing care to lifesaving air medical transportation. Our 38,000 team members and 7,000 physicians are committed to the health and well-being of the communities we serve, making Hackensack Meridian Health a distinguished leader in healthcare philanthropy. Hackensack University Medical Center is the first-ever New Jersey hospital to be ranked a Top 20 hospital in the nation. It is also ranked #1 in New Jersey and the New York metro area by U.S. News & World Report, 2025-26. Hackensack Meridian Health is proud to be home to New Jersey's #1 children's hospital and the state's only nationally-ranked cancer center, the John Theurer Cancer Center. To learn more, visit
Business Wire
6 days ago
- Health
- Business Wire
ZAP Surgical Celebrates 5,000th Patient Treated Globally with ZAP-X® Gyroscopic Radiosurgery® Platform
SAN CARLOS, Calif.--(BUSINESS WIRE)--ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced the treatment of the 5,000th patient using its ZAP-X® Gyroscopic Radiosurgery® platform — a major milestone reflecting the platform's rapid worldwide adoption. The case was performed at Hackensack Meridian Neuroscience Institute at Jersey Shore University Medical Center in Neptune, New Jersey. The patient, Christopher Czerwinski, a 64-year-old Trauma & ICU Nurse, was treated for a right-sided cavernous sinus meningioma. Mr. Czerwinski first noticed diplopia (double vision) nearly two years ago, with symptoms peaking in April 2025 while on vacation at Disney World with his wife — where he humorously recalls seeing two Cinderella castles. An ophthalmologist subsequently referred him for further testing, which led to an MRI and diagnosis. His condition was originally managed with prism glasses and contact lenses. Mr. Czerwinski ultimately selected Jersey Shore University Medical Center for his radiosurgical care due to the capabilities of the ZAP-X platform and the proven expertise of the medical team. Mr. Czerwinski underwent ZAP-X treatment and tolerated the procedure exceptionally well, resuming his active lifestyle immediately thereafter. 'Stereotactic radiosurgery continues to redefine how we manage challenging cranial conditions,' said Shabbar F. Danish, M.D., FAANS, chair of Neurosurgery, Hackensack Meridian Neuroscience Institute at Jersey Shore University Medical Center and professor of Neurosurgery, Hackensack Meridian School of Medicine. 'With the precision and versatility of ZAP-X, we were able to deliver focused treatment while minimizing exposure to surrounding critical structures. Mr. Czerwinski's case is a prime example of how we can address complex tumors while preserving quality of life.' An avid runner and budding pianist, Mr. Czerwinski also enjoys photography, working out with his wife, and spending time with friends and family. As a healthcare provider himself, he expressed deep appreciation for the compassionate care he received and the non-invasive nature of the ZAP-X procedure. 'I'm pleased our clinical experts have enabled the communities we serve to receive this advanced procedure at our academic medical center, without the need to travel far from home,' said Vito Buccellato, MPA, LNHA, president and chief hospital executive of Jersey Shore University Medical Center. The ZAP-X platform represents a new frontier in cranial radiosurgery. By employing gyroscopic beam delivery, ZAP-X can direct radiation from thousands of angles to concentrate dose on the tumor while sparing healthy brain tissue and helping protect nearby organs at risk, such as the optic nerves and brainstem. The procedure is painless, incisionless, and often completed in a single outpatient session — without the need for anesthesia or hospital admission. 'The treatment of our 5,000th patient not only represents a numerical milestone, but a reaffirmation of our mission to make brain radiosurgery safer, smarter, and more accessible,' said John R. Adler, M.D., founder and CEO of ZAP Surgical, and Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University. ZAP-X is the first and only dedicated cranial SRS platform that does not require radioactive Cobalt-60. Instead, it uses a modern linear accelerator to generate radiation, eliminating the safety, storage, and regulatory challenges associated with isotope-based systems. Furthermore, ZAP-X is the only vault-free solution in its category, thereby allowing installation in clinical settings with interior and exterior facing windows. 'We recruited experts in their fields, Dr. Shabbar Danish and Dr. Timothy Chen, in part so that we could add to the available, leading-edge treatment technologies at Jersey Shore and HMH,' said Kenneth N. Sable, M.D., MBA, FACEP, president, Acute Hospital Division, Hackensack Meridian Health. 'I'm thrilled that the 5,000th patient to receive ZAP-X treatment is from our local community.' For information about Jersey Shore University Medical Center's ZAP-X program, visit About ZAP Surgical Systems, Inc. ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X® Gyroscopic Radiosurgery® platform. ZAP was founded in 2014 by Dr. John R. Adler, Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University. Dr. Adler is also renowned as the inventor of the CyberKnife® system and founder of Accuray, Inc. The ZAP-X platform incorporates a unique vault-free design that typically eliminates the need for costly shielded treatment rooms. ZAP-X also utilizes a modern linear accelerator to eliminate legacy use of Cobalt-60. Learn more at and follow us on LinkedIn. ABOUT HACKENSACK MERIDIAN HEALTH Hackensack Meridian Health is a leading not-for-profit health care organization and New Jersey's largest, most comprehensive, and integrated health network. Our network includes 18 hospitals, more than 500 patient care locations, and a complete range of services from innovative research and life-enhancing care to lifesaving air medical transportation. Our 38,000 team members and 7,000 physicians are committed to the health and well-being of the communities we serve, making Hackensack Meridian Health a distinguished leader in healthcare philanthropy. Hackensack University Medical Center is the first-ever New Jersey hospital to be ranked a Top 20 hospital in the nation. It is also ranked #1 in New Jersey and the New York metro area by U.S. News & World Report, 2025-26. Hackensack Meridian Health is proud to be home to New Jersey's #1 children's hospital and the state's only nationally-ranked cancer center, the John Theurer Cancer Center. To learn more, visit
Yahoo
30-05-2025
- Business
- Yahoo
Galaxy Therapeutics Completes Enrollment of Primary Cohort in Pivotal SEAL IT IDE Trial
MILPITAS, Calif., May 30, 2025 /PRNewswire/ -- Galaxy Therapeutics, a privately held, clinical-stage medical device company focused on treating brain aneurysms, today announced the completion of enrollment in the primary cohort of its SEAL IT IDE trial. The trial's primary arm, known as the WNBA subgroup (Wide Neck Bifurcation Aneurysms from 2,0mm to 19,0mm of width), has successfully enrolled 163 patients across leading U.S. neurointerventional centers. The study is being conducted under an FDA Investigational Device Exemption (IDE) and is a key step toward eventual Premarket Approval (PMA). "We are proud to have reached this important milestone," said Dr. David Altschul, Principal Investigator of SEAL IT and Chief of Neurointerventional Surgery at Montefiore Medical Center. "This trial represents the first prospective multicenter U.S. study evaluating the SEAL device for wide-neck bifurcation aneurysms — one of the most challenging anatomical presentations in our field." Dr. Brian Jankowitz, also Principal Investigator and Chief of Neurosurgery and Co-Chair of Stroke and Neurovascular Program at the Hackensack Meridian Neuroscience Institute at JFK University Medical Center in Edison, New Jersey, added: "The SEAL device has consistently demonstrated ease of use and promising early outcomes in the investigation, in both ruptured and unruptured aneurysms. Completing enrollment in the primary cohort is an important achievement as we continue generating high-quality clinical evidence to support its use." The SEAL IT trial continues to enroll patients in two additional cohorts evaluating use of the device with sidewall and ruptured aneurysms, with 52 patients planned for enrollment in each subgroup. In total, the SEAL device has been used in more than 300 patients worldwide across Galaxy-sponsored clinical studies. Developed by physicians for physicians, the SEAL implant is a proprietary, self-expanding intrasaccular device designed to promote durable aneurysm occlusion without the need for adjunctive devices. It has shown encouraging safety and efficacy in earlier clinical studies including Pre-SEAL IT, which enrolled 33 patients at multiple international sites. About Galaxy Therapeutics Galaxy Therapeutics is a private, U.S.-based clinical-stage medical device company founded by four practicing neurointerventional physicians. The company has developed a novel implant technology for the treatment of brain aneurysms and holds multiple patents across the U.S., EU, China, and other key markets. Headquartered in Milpitas, California, Galaxy Therapeutics is advancing multiple clinical programs globally and is committed to delivering effective, evidence-based solutions to physicians and patients. For more information, visit follow the company on Linkedin or please contact: Sergi López García, sergi@ contact@ +34690926013 Logo - View original content to download multimedia: SOURCE Galaxy Therapeutics
